The Philadelphia chromosome translocation t(9;22)(q34;q11) may give rise to different BCR/ABL fusion mRNAs due to different genomic breakpoints and alternative splicing. The e1a2, b2a2 or b3a2 and c3a2 fusion mRNAs encode distinct fusion proteins (p190, p210 and p230, respectively), which are associated with different forms of leukemogenesis in humans and animal models. Our patient presented with acute pre-B cell lymphoblastic leukemia (ALL) with normal cytogenetics. After 3 years of standard ALL therapy, he relapsed with t(9;22)-positive chronic myelogenous leukemia (CML). Retrospective molecular analyses of the pre-treatment pre-B cell ALL sample showed the b3a2 (p210) and e1a2 (p190) BCR/ABL fusion transcripts. Only the b3a2 (p210) transcript was detected at relapse. Southern and immunoglobulin heavy chain (IgH) analyses of the presentation and relapse samples revealed an identical BCR rearrangement in both samples. However, only the ALL sample harbored an IgH gene rearrangement. These findings show a clonal relationship between the more differentiated pre-B cell and less differentiated CML clones and that the p210 and p190 fusion mRNAs were alternatively spliced from a single genomic breakpoint. Our patient's unusual molecular findings provide circumstantial evidence that the p190 protein may promote a more differentiated phenotype in a comparatively less differentiated p210-transformed precursor cell.
Introduction
The Philadelphia chromosome (Ph1) is a balanced reciprocal translocation, t(9;22)(q34;q11.2), associated with chronic myelogenous leukemia (CML) and acute leukemias of the lymphoid and myeloid lineages. While the vast majority of patients with CML have an associated t(9;22), this translocation also occurs in 20-30% of adults and only 2-5% of children with acute lymphoblastic leukemia (ALL).
1,2 The t(9;22) results in the juxtaposition of the Abelson gene (ABL) on chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11 to yield a variety of BCR/ABL fusion transcripts. 3 Each of these BCR/ABL fusion transcript variants is associated with biologically and clinically distinct forms of leukemogenesis. The majority of patients with CML have BCR breakpoints involving two different exons (b2 or b3) in the 8.5 kb major breakpoint cluster (M-BCR). Fusion of either of these exons to ABL common exon II yields two distinct mRNA fusion transcripts (referred to as b2a2 or b3a2), each of which encode distinct p210BCR-ABL fusion proteins. More rarely, patients with CML may have BCR breakpoints outside the M-BCR cluster. Such variants include the e19a2 fusion (fusing BCR exons 1-19 to common exon II of ABL) encoding a p230BCR-ABL fusion protein associated with the chronic neutrophilic variant of CML, 4 the CML-associated e6a2 BCR/ABL fusion mRNA encoding a protein slightly larger than 185 kDa, 5 and rare CML cases lacking ABL exon 2. 6 In contrast, the majority of children with Ph1-positive ALL, nearly 50% of adults with ALL, and rare CML pateints have a distinct set of BCR breakpoints within the large first BCR intron 1 (referred to as the minor breakpoint cluster region). Such genomic breakpoints lead to a distinct e1a2 BCR/ABL fusion from mRNA and a p190 fusion protein. 7 While all of the various BCR-ABL fusion mRNAs proteins share a relatively similar carboxy terminal ABL tyrosine kinase domain, they differ considerably in their BCR domains. Clearly, the various BCR/ABL fusion proteins contain a number of moieties that mediate intracellular signalling events. The ABL carboxy terminal tyrosine domain, BCR SH2-binding domains and dbl-like domains are thought to play key roles in pluripotential cell transformation. 8, 9 How the inclusion or exclusion of these various signalling moieties in the different BCR/ABL fusions promotes different forms of leukemogenesis is currently of great interest. In comparison to the p210BCR-ABL fusion which is associated with multilineage leukemogenesis after a relatively long latency period in animal models, the p190BCR-ABL protein has been shown to be more actively transforming and appears to have an accelerated propensity for promoting more differentiated acute B cell lineage leukemias in two mouse models. 10, 11 In humans, the p190BCR-ABL fusion has been associated with acute, more 'differentiated' and aggressive leukemias having either differentiated B cell or myeloid features. 12, 13 We describe an adolescent male who first presented with acute pre-B cell ALL containing one BCR genomic rearrangement and two BCR/ABL fusion transcripts (b3a2 and e1a2) arising through alternative splicing. These more differentiated pre-B cells were also characterized by a clonal rearrangment of the immunoglobulin heavy (IgH) chain locus.
Case report
A 13-year-old white male presented with a 1-month history of fatigue, lethargy and weight loss. Physical examination was remarkable for pallor, lymphadenopathy and moderate hepatospenomegaly. The complete blood count showed a leukocyte count of 96.8 × 10 9 cells/l with 1% banded neutrophils, 12% lymphocytes and 87% blasts, a hemoglobin of 88 g/l, and a platelet count of 142 × 10 9 cells/l. The chest radiograph and cerebral spinal fluid were normal. His bone marrow was replaced with Ͼ95% blasts having FAB L1 morphology. The surface marker profile showed expression of CD10, CD19, CD20, CD34, CD38, HLA DR and cytoplasmic (CD13 and CD33 were negative). Routine cytochemical stains for Tdt, myeloperoxidase, and Periodic Acid Schiff (PAS) were positive only for Tdt. The initial bone marrow karyotype from unstimulated cells showed 46,XY in 14 out of 20 metaphases without evidence for chromosomal translocations (chromosomes 5, 7, 10, 14, and 17 were randomly lost in six cells). The patient was diagnosed with pre B-lineage ALL and achieved complete remission following a modified LSA2-L2 regimen. 14 After 33 months of therapy, the patient's WBC gradually increased to 128.0 × 10 9 cells/l, and had a differential of 1% myeloblasts, 2% myelocytes, 10% metamyelocytes, 9% bands, 49% neutrophils, 18% lymphocytes, 1% basophils, 6% eosinophils and 3% monocytes; basophilia eventually increased to 6%. Auer rods were not observed. The hemoglobin concentration was 138 g/l, and platelet level was 196 × 10 9 cells/l. The patient's physical examination and state of health remained normal despite the hyperleukocytosis. Peripheral blood and bone marrow aspirate morphologies were consistent with CML. Cytogenetic analyses of blood and bone marrow showed t(9;22)(q34;11.2) in 39 of 40 metaphases. The patient achieved morphologic remission with hydroxyurea and subsequently underwent a successful 5/6 HLA-matched allogeneic bone marrow transplant. He is currently alive and well 9 years from transplantation without hematological evidence for dysplasia.
Materials and methods

Immunophenotypic and flow cytometric studies
Initial single-color flow cytometric studies were performed as previously described. [15] [16] [17] Briefly, leukemic blasts isolated with standard Ficoll-Hypaque centrifugation were labeled with a panel of primary mouse anti-human monoclonal antibodies, followed by an FITC-conjugated goat anti-mouse Fab2 second-step reagent. For controls, cells were incubated with the second-step reagent alone to determine background nonspecific fluorescence, and with directly conjugated mouse Ig proteins of the same isotype as the primary antibody plus the second-step reagent to rule out non-specific Fc binding. Multicolor studies were performed using primary antibodies directly conjugated to fluorescein (FITC) or phycoerythrin (PE). Analysis was performed on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA).
TdT determination was performed on cold methanol-fixed cytospins of the leukemic blasts stained with a rabbit antihuman antiserum (Becton Dickinson, San Jose, CA, USA) followed by a fluoresceinated goat anti-rabbit second step reagent (Becton Dickinson). Cells were then analyzed with a Leitz fluorescence microscope.
Southern blotting analyses
DNA was extracted from thawed, previously cryopreserved cells, digested with BglII, BamHI, and HindIII in accordance with the supplier's recommendations, electrophoresed in 0.7% agarose gels and transferred to nitrocellulose membranes, as described in previous publications from this laboratory. 18 Restriction analysis was used to detect and map BCR breakpoints using the BCR2 and BCR3 genomic probes, as defined by HindIII/BglII restriction endonucleases and a 4.9 kb BglII genomic band, respectively. 19 Samples for IgH rearrangement analysis were hybridized with 32 P-dCTP nick-translated DNA insert fragments using a J H probe (the gift of Dr P Leder, Harvard Medical School, Boston, MA, USA), a J k probe (Dr P Leder), and a C probe (a gift of Dr Korsmeyer, Washington University School of Medicine, St Louis, MO, USA). Blots were autoradiographed at −70°C using Kodak XAR-5 film and intensifying screens for 1-10 days.
Reverse-transcription polymerase chain reaction (RT-PCR)
Aliquots of bone marrow-derived RNA (1 g total) were reverse transcribed into cDNA and amplified for Ph1-associated BCR/ABL fusions, as previously described. 20 Briefly, the RNA was mixed with 100 pmole/ml random hexamers, 10 mM dNTP (Boehringer Mannheim, Indianapolis, IN, USA), 200 units/l reverse transcriptase enzyme (GIBCO, Gaithersburg, MD, USA), 40 unit/ml RNasin (Promega, Madison, WI, USA) and 10 × PCR Buffer (Perkin Elmer Cetus, Foster City, CA, USA). Reverse transcription was performed at 23°C for 10 min, 42°C for 60 min, and 95°C for 5 min in a Perkin Elmer thermocycler. Analysis of the M-bcr rearrangements consisted of a 5Ј BCR exon 11 primer-GGAGCTGCAGATGCTGAC-CAAA and a 3Ј ABL exon 2 primer-TCAGACCCTGAGCTC-AAAGTC. Analysis of the m-bcr locus consisted of a 5Ј BCR exon 1 primer CGCATGTTCCGGGACAAAAGC and the 3Ј ABL exon 2 primer as described above. The cDNA from patient samples and controls was mixed with the M/m-bcr and abl primers (20 pm/ml), 10 × PCR buffer and 20 pm/ml Taq polymerase (Perkin Elmer Cetus) and cycled at 95°C for 30 s, 55°C for 30 s and 72°C for 1 min, for a total of 40 cycles. Cell lines with known BCR-ABL fusions were purchased from American Type Culture Collection and used as positive controls for the M-bcr b3/a2 fusion (culture K562), M-bcr b2/a2 fusion (culture BV173), m-bcr e1/a2 fusion (culture SUPB15) and primers for ␤2 microglobulin were used as an internal positive control. The amplified cDNA samples were electrophoresed in a 0.8% agarose gel, transferred to nylon membranes and hybridized at 65°C for 5 h with radiolabelled oligonucleotide probes designed to detect M-bcr b3/a2, b2/a2 and m-bcr e1/a2 fusions. The probe sequence used to detect the b3a2 fusion was GCTGAAGGGCTT/TTGAACTCT-TGCTTA, for the b2a2 fusion the probe sequence was GCT-GAAGGGCTT/CTTCCTTATTGATG, and for the e1a2 fusion the probe sequence was GCTGAAGGGCTT/CTGCGTCTC-CAT. The cDNA-treated membranes were washed with increasingly stringent SSC and SDS solutions, air dried and exposed to XAR X-ray film (Eastman Kodak, Rochester, NY, USA) for 2 to 7 days at −70°C.
Cytogenetic studies
Analyses were performed on bone marrow or unstimulated blood samples on direct preparations or after short-term culture. All cases were G-banded, using standard GTG procedures. Where possible, at least 20 metaphases were examined from each specimen and karyotyped according to standard ISCN criteria.
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Results
The morphologic features, absence of cytoplasmic and expression of CD10, CD19 and CD20 on the blasts at presentation were diagnostic of pre-B lineage ALL. When the patient relapsed 33 months later on ALL-type therapy with myeloblasts, peripheral basophilia, and a t(9;22), a diagnosis of CML was made. In order to determine the clonal relationship between the initial pre-B cell acute leukemia clone and the subsequent relapsed CML, DNA was isolated from pre-treatment leukemic cells in the initial ALL and relapse CML sample and BCR rearrangements in the pre-B cell ALL sample and in the CML relapse (Figure 1) . 20 Once the clonal relationship of these two forms of leukemia in the same patient was established we undertook RT-PCR analysis to determine the precise BCR/ABL b3a2 fusion present at each time. Surprisingly, while similar levels of the BCR/ABL b3a2 fusion mRNA was detected in both the pre-B cell acute leukemia sample and the CML relapse (Figure 2a) , the pre-B cell ALL sample was distinguished by the simultaneous presence of the p190 e1a2 fusion mRNA as well (Figure 2b) .
Immunoglobulin gene rearrangement studies were undertaken to further investigate the level of cellular differentiation of the leukemic clone at both time points. The IgH was clonally rearranged only in the initial pre-B cell ALL sample while the IgK and IgH loci were in the germline configuration ( Figure 3 ). The subsequent CML relapse revealed no evidence for clonal rearrangement of the heavy or light chain immunoglobulin genes. 
Discussion
This report demonstrates an adolescent male who presented with a Ph1-negative pre-B cell ALL. Our molecular studies showed the presence of both the p210 and p190 fusion mRNAs along with a clonal rearrangement of the IgH locus, indicating a differentiated B cell phenotype. Subsequently, this child relapsed with CML in which both expression of the p190BCR-ABL fusion protein and the clonal IgH rearrangement were lost, consistent with the evolution of this patient's disease to a less differentiated multi-lineage clone. The clonal relationship of the initial pre-B cell ALL and the subsequent CML were established by the presence of an identical clonal BCR rearrangement detected by Southern analysis using BRC2 and BRC3 probes. These studies provide a human model where the role of the p190 fusion protein may promote the differentiation of a multi-lineage p210-containing precursor into a more differentiated B cell precursor.
The clinical course and molecular findings in our patient are distinctly different from other cases of Ph1-positive leukemia where p190 and p210 fusions were found to be co- expressed. In three children with co-expression of p190 and p210 fusions (two with ALL, one with CML), one child's e1/a2 and b3/a2 mRNA levels were undetectable when RT-PCR was repeated during remission. 7 In three adults with CML and RT-PCR evidence for e1/a2 and b2/a2 (or b3/a2) junctions, two patients acquired detectable e1/a2 mRNA levels during myeloid blastic phases, leading to the interesting speculation that this junction may somehow have transformed the leukemia into a more 'aggressive' disease. 22 Our patient's molecular findings also stand apart from another child who, having phenotypic ALL at presentation and CML at relapse, had the same clonal IgH rearrangement and b2/a2 mRNA pattern at both time points, and was reasoned to have presented with CML in 'lymphoid' blast crisis. 23 In 25 adults with CML, Saglio et al 24 reported trace e1/a2 mRNA levels accompanying b2/a2 or b3/a2 mRNA fusions in highly amplified RT-PCR samples (60 cycles with nested primers). The biologic and clinical significance of these low levels of the BCR/ABL e1/a2 fusion in the setting of CML is unclear.
The role of the specific BCR domains and how their inclusion/exclusion in the various BCR/ABL fusion mRNAs plays a role in determining the biologic and clinical features of the resultant leukemia is of interest. While the p190BCR-ABL (e1/a2) fusion has been associated with more acute, differentiated leukemias, and patients with p210BCR-ABL (b3a2 or b2/a2) or the p230BCR-ABL (e19a2) are more likely to have chronic leukemias, the b3/a2 or b2/a2 junctions have been identified in patients presenting with acute leukemia as well. Thus, the specific BCR/ABL fusion type alone does not always independently determine leukemia phenotype and biology. 4, 7, 25, 26 Further genetic mutations may determine biology and phenotype as well. In this regard, evidence exists that MYC proteins are essential to p190BCR-ABL-induced transformation of hematopoietic cells into B-lineage differentiation. 27 Our patient's leukemic phenotype appeared to vary with the presence of the BCR/ABL e1/a2 fusion suggesting that this transcript may play a role in B-lineage cellular differentiation or, alternatively, in the specific transformation of a differentiated B cell precursor.
Ph1-positive ALL requires intensive therapy to induce and maintain remission. 28, 29 Patients with CML, however, tend to respond to medicines that are quite dissimilar to those required for the treatment of ALL. 30 Our patient's clinical course and molecular findings raises questions about what effects chemotherapy may have on the mechanisms of cellular differentiation. It is currently unclear whether patients with coexpression of the e1/a2 and b2/a2 or b2/a3 fusion transcripts are at increased likelihood to present with ALL and relapse with CML during the course of therapy, and if so, what management strategies might prevent failure. A systematic study of patients with co-expression of BCR-ABL junctions may also provide important information about the treatment of Ph1-associated leukemias.
